A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy in Hematological Centers in Belgium Using Gene Expressing Profiling From Baseline Bone Marrow.
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Deferasirox (Primary)
- Indications Myelodysplastic syndromes
- Focus Pharmacodynamics
- Acronyms EXPHAR
- Sponsors Novartis
- 20 Jul 2017 Status changed from recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 08 Feb 2017 This trial has been Discontinued in Belgium according to European Clinical Trials Database record.